For each of the below topics, a slot in the programme will be available for an oral communication selected out of the submitted abstracts.
- Artificial Intelligence, Big Data, Machine Learning in Drug Discovery
Session Chair : Dr Eric HAAKSMA, Boehringer Ingelheim, Austria
Session Chair : Dr Wolfgang JAHNKE, Novartis Institutes for Biomedical Research, Switzerland
Session Chair : Dr Sharan BAGAL, AstraZeneca, United Kingdom
This session will be put together by selected proposals out of the abstract submissions.
- Frontiers of Synthetic Chemistry
Session Chair : Prof. Erick M. CARREIRA, ETH Zürich, Switzerland
- Innovation and Inspiration from Natural Products
Session Chair : Prof. Thomas MAGAUER, University of Innsbruck, Austria
- Predictive ADME Sciences: Striking a Balance Between In Silico and Experimental Work?
Session Chair : Dr Amit KALGUTKAR, Pfizer, United States
- Protein Degradation: New Rules for Drug Discovery
Session Chair : Prof. Alessio CIULLI, University of Dundee, United Kingdom
Until recently, small molecules drug discovery has been predicated on blockade/inhibition of a target protein as the conventional modality of intervention. Today, inducing protein degradation by means of bivalent “PROTACs” or monovalent “molecular glues” is revolutionizing how medicinal chemists target proteins and is redefining their “rule set”. This section will outline the opportunities and challenges involved with targeting proteins for degradation, highlight the latest advances in the field, and cover recent successes and learning from medicinal chemistry campaigns.